MDT-AP-2389
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 20.4
- os_event
- false
- age_years
- 11.07
- sex
- M
- new_clusters
- C6
- umap1_2d
- 4.834010787
- umap2_2d
- 6.050894035
- umap1_3d
- 1.528373243
- umap2_3d
- 0.348234318
- umap3_3d
- -1.418613586
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.410
- PANCREAS_BETA_CELLS+0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- KRAS_SIGNALING_DN+0.310
- XENOBIOTIC_METABOLISM+0.310
- FATTY_ACID_METABOLISM+0.290
- DNA_REPAIR+0.240
- ESTROGEN_RESPONSE_LATE+0.230
- ALLOGRAFT_REJECTION+0.210
- COAGULATION+0.200
Top 10 suppressed
- TGF_BETA_SIGNALING-0.500
- UV_RESPONSE_DN-0.460
- WNT_BETA_CATENIN_SIGNALING-0.440
- MITOTIC_SPINDLE-0.420
- PROTEIN_SECRETION-0.370
- MYC_TARGETS_V2-0.350
- ANDROGEN_RESPONSE-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.280
- NOTCH_SIGNALING-0.270
- MTORC1_SIGNALING-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2120 | Med | Medulloblastoma | 0.809 |
| 2 | MDT-AP-2628 | Med | Medulloblastoma | 0.802 |
| 3 | MDT-AP-2299 | Med | Medulloblastoma | 0.791 |
| 4 | TCGA-LL-A5YL-01A-12R-A29R-07 | — | B | 0.785 |
| 5 | SRR1410656 | GTEX | — | 0.778 |
| 6 | SRR1323764 | GTEX | — | 0.761 |
| 7 | MDT-AP-2618 | Med | Medulloblastoma | 0.758 |
| 8 | TCGA-S5-A6DX-01A-11R-A31N-07 | — | — | 0.752 |
| 9 | TCGA-AO-A03T-01A-21R-A034-07 | — | B | 0.731 |
| 10 | MDT-AP-0572 | Med | Medulloblastoma | 0.728 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.410 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.310 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.310 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| COMPLEMENT | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.130 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| MYOGENESIS | 0.120 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |